Abbott’s Volt pulsed field ablation system — for the treatment of atrial fibrillation. The Volt system delivers high-energy electrical pulses to targeted areas of the heart to disrupt abnormal rhythms ...

Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) has approved the company's Volt™ PFA System to treat patients battling atrial fibrillation (AFib). Abbott will soon begin ...

Abbott today announced the U.S. Food and Drug Administration (FDA) has approved the company's Volttm PFA System to treat patients battling atrial fibrillation (AFib). Abbott will soon begin commercial ...

Abbott has announced the company has received approval from the U.S. Food and Drug Administration (FDA) for its Volt PFA ...

Abbott (NYSE: ABT) announced today that the FDA approved its Volt pulsed field ablation (PFA) system to treat patients with AFib.

After claiming its approval in Europe earlier this year, Abbott has secured the FDA’s go-ahead for its Volt pulsed field ablation system for irregular heart rhythms, a step forward in an | With the U.

US FDA approves Abbott's Volt PFA System to treat patients with atrial fibrillation: Abbott Park, Illinois Wednesday, December 24, 2025, 12:00 Hrs [IST] Abbott, is a global health ...

I felt fine, but my Whoop data told a different story. Paying attention led to early detection and a successful treatment.

Columbus Regional Health Electrophysiology team completes 500th ablation case for treating irregular heartbeats ...

The US Food and Drug Administration (FDA) has granted approval for Abbott’s Volt PFA System, expanding treatment options for ...

New technology combines Pulsed Field Ablation (PFA) and Advanced Radiofrequency Ablation with AtriCure’s EnCompass ® clamp to reduce treatment time for surgical ablation patients MASON, Ohio, December ...